Table 2.
Standard triple therapy | Bismuth quadruple therapy | Sequential therapy | Concomitant therapy | P value1 | |
Mean age ± SD (yr) | 58.1 ± 11.6 | 58.5 ± 11.4 | 56.1 ± 11.5 | 56.9 ± 11.3 | 0.591 |
Male/Female (n) | 72/86 | 10/18 | 20/21 | 24/13 | 0.150 |
Smoking (n) | 28 (17.7) | 4 (13.8) | 8 (19.5) | 8 (21.6) | 0.904 |
Alcohol (n) | 35 (22.2) | 7 (24.1) | 10 (24.4) | 10 (27) | 0.851 |
HTN (n) | 34 (21.5) | 5 (17.2) | 6 (14.6) | 4 (10.8) | 0.451 |
DM (n) | 14 (8.9) | 3 (10.3) | 2 (4.9) | 2 (5.4) | 0.845 |
Endoscopic finding (n) | - | ||||
DU/GU | 55 | 1 | 6 | 8 | - |
CAG | 66 | 18 | 13 | 12 | - |
IM | 23 | 1 | 5 | 3 | - |
Erosive gastritis | 30 | 9 | 18 | 15 | - |
MALT lymphoma | 0 | 0 | 2 | 0 | - |
Pearson's χ2 test. HTN: Hypertension; DM: Diabetes mellitus; DU: Duodenal ulcer; GU: Gastric ulcer; CAG: Chronic atrophic gastritis; IM: Intestinal metaplasia; MALT: Mucosa associated lymphoid tissue.